Drug Related Hypertension: A Review on an Unappreciated Cause of Blood Pressure Increase
Blood pressure elevation is known to be a determining risk factor for cardiovascular disease and mortality. Although blood pressure increase has many causative factors, numerous drugs have also been reported to increase blood pressure. Drugs are often overlooked as a reason of hypertension. A few medications that usually help to reduce blood pressure may increase blood pressure paradoxically or may lead to blood pressure elevation on discontinuation due to a rebound effect. Detailed evaluation of patient’s medical therapy may help to identify the culprit drug. Discontinuation of the causative agent is recommended once the drug induced hypertension has been identified. The present review summarizes the therapeutic agents that can induce hypertension and would allow the clinician to recognize this entity and to take the appropriate therapeutic measures.
Elliott WJ. Drug interactions and drugs that affect blood pressure. J Clin Hypertens (Greenwich). 2006;8(10):731-7.
Lovell AR, Ernst ME. Drug‑Induced Hypertension: Focus on Mechanisms and Management. Curr Hypertens Rep. 2017; 19:39.
Salvetti M, Paini A, Bertacchini F, Stassaldi D, Aggiusti C, Agabiti Rosei C, et al. Acute blood pressure elevation: Therapeutic approach. Pharmacological Research.2018; 130:180–90.
Scalco AZ, Scalco MZ, Azul JB, Lotufo Neto F. Hypertension and depression. Clinics 2005;60(3):241-50.
Sander GE. Secondary hypertension Drugs and herbal preparations that increase pressure. Journal of the American Society of Hypertension. 2014; 8(12):946–8.
Thase ME. Effects of venlafaxine on blood pressure: a meta‑analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59(10): 502–508.
Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent Advances in Hypertension and Cardiovascular toxicities with VEGF Inhibition. Hypertension. 2017;70:220–6.
Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events. Journal of the American Society of Hypertension. 2018; 12(6): 409-25.
Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. Tyrosine Kinase Inhibitor‑Induced Hypertension. Curr Oncol Rep. 2018; 20(8):65.
Hayman SR, Leung N, et al. VEGF Inhibition, Hypertension, and Renal Toxicity Curr Oncol Rep. 2012 August; 14(4): 285–294.
Maitland, ML, Kasza KL, et al. Ambulatory monitoring detects sorafenib‑induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009; 15(19): 6250–6257.
Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology. 2004;22(14_suppl): 6098−6098.
Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, et al. The hypertension of Cushing’s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of Hypertension. 2015; 33: 44–60.
Hattori T, Murase T, Erika Iwase, Keiji Takahashi, Masafumi Ohtake, Koji Tsuboi, et al. Glucocorticoid‑induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. Nagoya J. Med. Sci.2013; 75: 81−92.
Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. J Natl Cancer Inst 2012; 104: 93–113.
Boughton Ch, Taylor D, et al. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole. Endocrinol Diabetes Metab Case Rep. 2018; 17–0157.
Auchusa RJ, Yub MK, et al. Use of Prednisone With Abiraterone Acetate in Metastatic castration‑Resistant Prostate Cancer. The Oncologist 2014; 19: 1231–1240.
Grossman A, Messerli FH, et al. Drug induced hypertension – An unappreciated cause of secondary hypertension. European Journal of Pharmacology. 2015; 763: 15–22.
Gyamlani G, Gerac SA. Secondary Hypertension due to Drugs and Toxins. Southern Medical Journal. 2007; 7(100):692−9.
Copyright (c) 2020 Kunal Marya et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.